MS2.2 FFM Case Review 1

25 minute read

Published:

Today, I had my first FFM (focused family medicine) session and I thought there were some cases that I wanted to review and learn more about, so I am recording my notes of these cases here.

1. Infant with infectious diarrhea

Case Summary

9 month old female infant presents with 3 days of cough, rhinorrhea, and diarrhea with 10 bowel movements/day. Coughing occasionally produces green sputum. The cough is worse when supine. Diarrhea is watery and dark. She has had stomach pain, which improved with Infant Tylenol (1 ml every 6-8 hours as needed). There has been no fever and vomiting. The mother is concerned because she heard wheezing sounds last night.

She was delivered a few weeks pre-term by C-section following an uncomplicated pregnancy. She has been otherwise healthy. She has been feeding well with formula and recent introduction fo solids. She lives with her mother and father, a dog and 2 cats. Both mother and father have had similar symptoms for the past couple weeks. There is no travel history. She and both parents are up to date on vaccinations. She is lactose intolerant.

Vitals are normal for her age. On exam, she appears well and energetic, with no abnormal findings.

Problem representation

9 month old female infant presents with acute cough, rhinorrhea, and watery diarrhea, with no abnormal exam findings.

CDM grid

RankDiagnosisSupportingRefuting
1Acute viral upper respiratory infectionShort duration (3 days); cough and rhinorrhea; no fever; similar symptoms in both parents; normal vitals and exam; green sputum can occur with viral illness due to neutrophils and post-nasal drainageNo significant lower respiratory signs on exam (no wheeze, crackles, retractions); cough productive description may be caregiver interpretation
2Acute viral gastroenteritis (e.g., norovirus, adenovirus)Watery, dark diarrhea with high frequency (10/day); mild abdominal pain; no blood or mucus; no fever or vomiting; sick contacts in household; well-appearing infantNo signs of dehydration; continues to feed well; diarrhea only 3 days in duration
3Viral bronchiolitis (e.g., RSV)Age <1 year; rhinorrhea and cough; caregiver-reported wheezing; worse when supineNormal respiratory exam (no wheeze, crackles, or increased work of breathing); normal vitals; energetic and feeding well
4Post-nasal drip–related coughCommon in infants with viral URIs; cough worse when supine; green sputum likely swallowed nasal secretions; nocturnal “wheezing” may represent upper airway soundsDoes not explain diarrhea; diagnosis of exclusion; no direct visualization of post-nasal drainage
Critical 1PneumoniaCough; caregiver concern for wheezeNo fever; no tachypnea; no hypoxia; normal lung exam; well appearance
Critical 2Dehydration secondary to gastroenteritisHigh stool frequencyNormal skin turgor; moist mucous membranes; normal capillary refill; normal fontanelle; feeding well; energetic
Critical 3SepsisYoung ageAfebrile; normal vitals; well-appearing; no lethargy, irritability, or poor feeding

Notes

  • Assess for signs of dehydration: urine output (no. of wet diapers - difficult to assess here due to diarrhea), tears, mucous membranes, and capillary refill
  • Monitor for progression: work of breathing, wheezing, new fever
  • Indications for infectious diarrhea panel:
    • Mild-moderate symptoms ≥ 7 days
    • Severe symptoms:
      • ≥ 10 stools/day
      • bloody stools
      • fever ≥ 38.5c
      • pain
    • Severe immunocompromise, e.g. cancer, transplant, or untreated HIV
  • Presence of blood or mucus in stool suggests bacterial pathogens
  • Viral testing only if symptoms worsen
  • No routine labs or imaging unless changes in clinical status

Management of infectious diarrhea [1]

  • Modify or discontinue antimicrobial therapy once a clinically plausible organism is identified.
  • Continue human milk feeding in infants and children throughout the diarrheal episode.
  • Resume age-appropriate usual diet during or immediately after completion of rehydration.

Symptomatic Therapies

Antimotility Agents

  • Not recommended in children <18 years with acute diarrhea (strong, moderate).
  • Loperamide:

    • May be used in immunocompetent adults with acute watery diarrhea (weak, moderate).
    • Avoid at any age in:

      • Suspected or confirmed inflammatory diarrhea
      • Diarrhea with fever
      • Risk of toxic megacolon (strong, low)

Antiemetics

  • Ondansetron may be used to facilitate oral rehydration in:

    • Children >4 years
    • Adolescents with vomiting from acute gastroenteritis (weak, moderate)

Empiric Antimicrobial Therapy

Acute Watery Diarrhea

  • Not recommended in most patients without recent international travel (strong, low).
  • Exceptions:

    • Immunocompromised individuals
    • Young infants who are ill-appearing
  • Avoid empiric therapy in:

    • Persistent watery diarrhea ≥14 days (strong, low)
  • Asymptomatic contacts:

    • Do not offer empiric or preventive therapy

Bloody Diarrhea

  • In immunocompetent children and adults, empiric therapy while awaiting results is not recommended (strong, low), except:

    • Infants <3 months with suspected bacterial etiology
    • Ill immunocompetent patients with:

      • Documented fever
      • Abdominal pain
      • Bloody diarrhea
      • Features of bacillary dysentery (frequent scant bloody stools, fever, cramps, tenesmus), presumptively due to Shigella
    • Recent international travelers with:

      • Temperature ≥38.5°C
      • Signs of sepsis (weak, low)
  • Asymptomatic contacts of patients with bloody diarrhea:

    • Do not offer empiric therapy
    • Advise infection prevention and control measures
  • Adults:

    • Fluoroquinolone (eg, ciprofloxacin) or
    • Azithromycin
    • Choice depends on local susceptibility patterns and travel history (strong, moderate)
  • Children:

    • Third-generation cephalosporin:

      • Infants <3 months
      • Children with neurologic involvement
    • Azithromycin as an alternative based on local resistance and travel history (strong, moderate)

Rehydration therapies

Degree of DehydrationRehydration TherapyReplacement of Losses During Maintenance
Mild to moderate dehydrationInfants and children: ORS 50–100 mL/kg over 3–4 hours
Adolescents and adults (≥30 kg): ORS 2–4 L
Infants and children:
• <10 kg: 60–120 mL ORS per diarrheal stool or vomiting episode (up to ~500 mL/day)
• >10 kg: 120–240 mL ORS per diarrheal stool or vomiting episode (up to ~1 L/day)

Adolescents and adults:
• Ad libitum, up to ~2 L/day

Replace losses as above as long as diarrhea or vomiting continues
Severe dehydrationInfants: Malnourished infants may benefit from smaller, frequent boluses of 10 mL/kg due to limited ability to increase cardiac output with large volumes

Children, adolescents, and adults: IV isotonic crystalloid boluses per current resuscitation guidelines (up to 20 mL/kg) until pulse, perfusion, and mental status normalize; adjust electrolytes and administer dextrose based on labs
Infants and children:
• <10 kg: 60–120 mL ORS per diarrheal stool or vomiting episode (up to ~500 mL/day)
• >10 kg: 120–240 mL ORS per diarrheal stool or vomiting episode (up to ~1 L/day)

Adolescents and adults:
• Ad libitum, up to ~2 L/day

Replace losses as above as long as diarrhea or vomiting continues. If unable to drink, administer via nasogastric tube or IV 5% dextrose in 0.25 normal saline with 20 mEq/L potassium chloride

2. AL amyloidosis with new-onset atrial fibrillation

Case Summary

A 50–70-year-old man with AL amyloidosis, nephrotic-range proteinuria, hypertension, and mild coronary artery disease presents with 1 week of productive cough and mild chest pain. Symptoms began 3 days after his monthly subcutaneous daratumumab injection.

The cough produces green sputum without hemoptysis. He denies progression of symptoms, dyspnea on exertion, or resting shortness of breath. He reports mild (2–3/10), diffuse anterior chest pain that is non-radiating and not exacerbated by exertion, stress, or position.

He denies lightheadedness, dizziness, syncope, palpitations, abnormal heart rate or rhythm awareness, fever, nausea, vomiting, or gastrointestinal association with meals. There is no history of trauma. He does not smoke, drink alcohol, or use recreational drugs.

His home medication includes ramipril, which he has not taken since yesterday.

Physical exam Vitals are stable. On exam, he is well-appearing and shows no signs of respiratory distress. Soft inspiratory crackles are heard at the bilateral lung bases. Heart rhythm is irregularly irregular. There are no murmurs. The rest of the cardiac and respiratory exam was normal.

Investigations ECG shows atrial fibrillation, with erratic baseline and ventricular rate of 95 bpm. Deep negative deflections are seen in V1-V2. In V2 only, QRS complexes are followed by upsloping ST elevation with tall T waves.

Chest X-ray (AP and lateral views):

  • Airway: midline trachea
  • Breathing: lungs symmetrically expanded; lung fields clear with normal vascular markings tapering peripherally
  • Circulation: cardiac silhouette normal in size; no mediastinal shift or widening; normal mediastinal contours and hila.
  • Diaphragm: costophrenic angles sharp bilaterally; gastric bubble present
  • Other: No fractures or skeletal abnormalities

Problem representation

50–70-year-old man with AL amyloidosis, nephrotic-range proteinuria, hypertension, and mild coronary artery disease presents with a subacute productive cough and mild, non-exertional anterior chest pain following recent daratumumab administration, found to have atrial fibrillation with anterior ECG abnormalities but a normal chest X-ray and stable vital signs.

CDM grid

DiagnosisSupporting FactorsRefuting / Lowering-Likelihood Factors
Acute bronchitis• Subacute onset of productive cough with green sputum
• Absence of systemic toxicity
• Normal chest X-ray (no consolidation)
• Inspiratory crackles can be present
• Immunosuppression from daratumumab ↑ infection risk
• Clinical diagnosis per AAFP in absence of pneumonia or chronic lung disease
• Green sputum is nonspecific
• Immunocompromised state raises concern for deeper infection
Community-acquired pneumonia (CAP)• Immunocompromised status (daratumumab)
• Radiographic findings may lag early in disease
• Mild or atypical presentations described in impaired immunity
• No fever
• No dyspnea
• Normal chest X-ray
• No systemic toxicity
Lower respiratory tract infection related to daratumumab• Daratumumab associated with ↑ risk of respiratory infections
• Timing relative to recent administration
• Cough and sputum production
• No severe systemic features
• Normal imaging
• Symptoms consistent with uncomplicated bronchitis
Atrial fibrillation with RVR–related chest discomfort• Irregularly irregular rhythm
• ECG consistent with AF
• Chest discomfort often mild, non-exertional in AF
• Known association per ACC/AHA/ESC
• Chest pain not clearly temporally linked to tachyarrhythmia
• Presence of respiratory symptoms suggests alternative cause
GERD / esophageal spasm• Atypical, non-exertional chest pain
• Lack of objective cardiac or pulmonary findings
• GI causes account for ~20% of outpatient chest pain
• Does not explain productive cough or sputum
• No clear reflux-associated symptoms reported
Pulmonary embolism (PE) (must not miss)• Increased thrombotic risk (amyloidosis, nephrotic syndrome)
• Can present with cough and mild chest pain
• No dyspnea
• No hemoptysis
• Normal chest imaging
• Overall low clinical suspicion; requires risk stratification (Wells/Geneva, D-dimer)
Acute coronary syndrome (ACS) (must not miss)• Chest pain in patient with known CAD and AF
• Mild or atypical presentations possible
• Non-exertional, mild pain
• No ischemic ECG changes reported
• No associated autonomic symptoms (e.g., diaphoresis)
Early infective endocarditis (must not miss)• Immunocompromised state
• Underlying cardiac disease (AF)
• Can present subtly in immunosuppressed patients
• Afebrile
• Normal cardiac exam
• No embolic or systemic signs

Management of amyloidosis

In AL amyloidosis, standard heart failure and arrhythmia algorithms often do not apply — management must be individualized, cautious, and coordinated across specialties.

1. Disease-Modifying Therapy

  • Cornerstone of treatment: Chemotherapy targeting the underlying plasma cell dyscrasia
  • Goal:
    • Halt amyloid light-chain production
    • Improve organ function and survival, particularly cardiac outcomes
  • Early initiation is critical and requires close hematology collaboration

Common Regimens

AgentRole / Notes
BortezomibProteasome inhibitor; backbone of many regimens
MelphalanAlkylating agent; often combined with steroids
DexamethasoneEnhances plasma cell suppression
DaratumumabAnti-CD38 monoclonal antibody; FDA-approved for AL amyloidosis in combination regimens

2. Heart Failure Management

  • Heart failure in AL amyloidosis is typically restrictive
  • Management focuses on symptom control, not traditional HFrEF remodeling

Volume Management (Mainstay)

StrategyKey Points
Loop diureticsUse lowest effective dose to avoid hypotension
Mineralocorticoid receptor antagonistsAdjunctive volume control
Sodium restrictionRecommended in all patients

Medications to Avoid or Use with Extreme Caution

Drug ClassReason
Beta-blockersPoor tolerance; may reduce cardiac output
ACE inhibitors / ARBsHigh risk of hypotension
Calcium channel blockersNegative inotropy; can worsen symptoms
  • These agents often worsen hemodynamics due to fixed stroke volume
  • If used, require very careful titration

Renal Considerations

  • Close monitoring of renal function is essential due to:
    • Nephrotic-range proteinuria
    • Direct renal amyloid deposition
    • Diuretic-induced hypovolemia

3. Arrhythmia and Atrial Fibrillation Management

Anticoagulation

  • Indicated for all patients with atrial fibrillation
  • Independent of CHA₂DS₂-VASc score
  • Rationale: markedly increased risk of:
    • Intracardiac thrombus
    • Systemic embolization
OptionNotes
DOACsAcceptable
WarfarinAcceptable
Bleeding riskMust be carefully assessed

Rhythm and Rate Control

StrategyRecommendation
Rhythm controlAmiodarone or dofetilide preferred
AvoidAgents with negative inotropic effects
Rate controlLow-dose beta-blockers only if tolerated

Cardioversion

  • Transesophageal echocardiography required before cardioversion
  • Necessary regardless of anticoagulation duration to exclude left atrial appendage thrombus

4. Device Therapy and Advanced Interventions

InterventionRole / Limitations
ICDLimited benefit; poor outcomes; ↑ infection & bleeding risk
LVADGenerally unfavorable risk–benefit profile
PacemakerConsider for recurrent syncope or advanced conduction disease
Heart transplantationReserved for select patients; reassessed during chemotherapy
  • Device decisions must consider:
    • Active chemotherapy
    • Infection risk
    • Limited survival benefit in advanced disease

5. Multidisciplinary and Supportive Care

  • Optimal care requires a multidisciplinary team, including:
    • Cardiology
    • Hematology
    • Nephrology
    • Other specialties as needed

Supportive Measures

  • Salt restriction
  • Careful diuretic titration
  • Management of:
    • Autonomic dysfunction
    • Bleeding diathesis
    • Renal impairment
    • Other comorbidities

Goal: Symptom relief, organ preservation, and complication prevention

Common infections in older adults with immunoglobulin light chain amyloidosis and proteinuria

The most common infections seen in older adults with immunoglobulin light chain amyloidosis and nephrotic-range proteinuria are bacterial respiratory tract infections (such as pneumonia and bronchitis), urinary tract infections, and skin/soft tissue infections. This increased susceptibility is due to several factors: AL amyloidosis is associated with functional hyposplenism, which impairs clearance of encapsulated bacteria (notably Streptococcus pneumoniae and Haemophilus influenzae); nephrotic-range proteinuria leads to urinary loss of immunoglobulins and complement proteins, further compromising humoral immunity; and older age itself is a risk factor for infection.

Patients with nephrotic syndrome, including those with AL amyloidosis, are also at increased risk for peritonitis and sepsis from gram-negative organisms due to impaired immune defenses. [2] Opportunistic infections may occur, especially in those receiving immunosuppressive therapy for underlying plasma cell dyscrasia. [1], [2] Viral infections (such as influenza and herpes zoster) are also more frequent in this population. [1]

Notes on amyloidosis [2]

The presence of an unexplained multisystem illness, fatigue, or organ dysfunction that does not fit common disease patterns should prompt evaluation for amyloidosis.

Pathogenesis

  • Systemic amyloidosis is defined by abnormal folding of a normally soluble precursor protein, leading to insoluble fibril deposition.
  • In AL (light-chain) amyloidosis, abnormal folding occurs due to:
    • Proteolytic events or
    • Amino acid sequence changes that render immunoglobulin light chains thermodynamically and kinetically unstable
  • Misfolded light chains self-aggregate and interact with:
    • Glycosaminoglycans
    • Serum amyloid P protein
  • These interactions promote amyloid fibril formation, stabilize tissue deposits, disrupt normal tissue architecture, and ultimately cause organ dysfunction.

Immunoglobulin Characteristics

  • Lambda light chains: 75–80%
  • Kappa light chains: 20–25%
  • Rare forms:
    • AH amyloidosis (heavy chain)
    • AH/AL amyloidosis (heavy + light chains)

Genetic Features

  • t(11;14) translocation:
    • Involves IgH locus and cyclin D1
    • Present in ~50% of AL amyloidosis cases
  • Hyperdiploidy:
    • Common in multiple myeloma
    • Seen in ~10% of AL amyloidosis cases
  • Somatic mutations in IGLV genes:
    • Encode the light-chain variable region
    • Reduce protein stability and facilitate fibril formation

Risk Factors

  • Exact risk factors remain unclear
  • Common associations:
    • Monoclonal gammopathy
    • Multiple myeloma
  • MGUS:
    • Relative risk: 8.8
    • ~1% incidence of AL amyloidosis in long-term follow-up
  • Multiple myeloma:
    • AL amyloidosis in 10–15%
    • 38% have Congo red–positive deposits
  • Additional associations:
    • Rising monoclonal free light chains precede diagnosis by >4 years
    • Possible association with Agent Orange exposure (limited evidence)
    • N-glycosylation of kappa light chains predicts earlier AL diagnosis in MGUS

Epidemiology

  • Data limited due to lack of comprehensive population registries
  • Incidence increases with age
MetricValue
Incidence (1950–1989, Olmsted County)8.9 / million person-years
Incidence (1970–1989)10.5 / million person-years
Incidence (1990–2015)12.0 / million person-years
Global crude incidence~10.4 / million person-years
Estimated global cases (past 20 yrs)~74,000
Estimated incidence (2018)10 / million population
Estimated 20-yr prevalence51 / million population
U.S. prevalence (2007 → 2015)15.5 → 40.5 / million
U.S. incidenceStable (9.7–14.0 / million person-years)

Clinical Presentation

2026-01-28-18-01-20

Clinical presentation of AL amyloidosis [[2]](#ref-2)

  • Typically rapidly progressive
  • Diagnosis often delayed due to:
    • Nonspecific early symptoms
    • Low clinician awareness
  • General
    • Fatigue
    • Weight loss
  • Renal (60–70%)
    • Nephrotic-range proteinuria
    • Hypoalbuminemia
    • Secondary hyperlipidemia
    • Edema
    • Renal failure may occur without proteinuria due to interstitial or vascular deposition
  • Cardiac (70–80%) — Leading cause of death
    • Early:
      • Low voltage ECG
      • Concentric ventricular thickening on echocardiography
      • Diastolic dysfunction
    • Other features:
      • Poor atrial contractility (even in sinus rhythm)
      • High risk of atrial thrombi and embolism
      • Elevated troponin and/or NT-proBNP
      • Bradyarrhythmias often precede terminal decompensation
  • Neurological
    • Small-fiber neuropathy
    • Autonomic dysfunction:
      • GI dysmotility
      • Early satiety
      • Dry eyes/mouth
      • Orthostatic hypotension
      • Neurogenic bladder
  • GI
    • Macroglossia: 10–20%
    • Liver:
      • Hepatomegaly
      • Cholestasis
      • Hyperbilirubinemia (often terminal)
    • Spleen: Functional hyposplenism (not splenomegaly)
  • Hematologic / Cutaneous:
    • Easy bruising
    • Factor X deficiency
    • Ecchymoses
    • Nail dystrophy
    • Alopecia
  • Musculoskeletal: Amyloid arthropathy

3. Painful knee after fall

I think this is an interesting case because, as I mention below, I felt the patient had difficulty understanding what I was saying, even though I was speaking in Cantonese. Granted, she had hearing aids and I might have been speaking too quietly for her to hear. Further, she seemed to be able to understand my English-speaking preceptor and follow most of his commands without trouble during the physical exam. Nonetheless, OpenEvidence seems to believe that this case involves a central neurological process: link to OpenEvidence chat.

Case Summary

62-year-old woman presents with 1 month of progressive left knee pain and left leg weakness. Two weeks ago, she fell while descending stairs and landed directly on her left patella. She attributes the onset of her knee pain to this fall.

She is accompanied by her brother, who lives with her. He reports observing progressive difficulty with walking that began several years ago. He notes that her knee pain began worsening approximately 1 month ago, which was prior to the fall that occurred 2 weeks ago.

The patient has no chronic medical conditions. She takes no regular medications.

The patient communicates primarily using short phrases and gestures. Her brother provides most of the historical information during the interview. She appears to occasionally not understand or hear when addressed in Cantonese, which is her primary language, by either myself or her brother.

Physical exam [3]

  • General Appearance: The patient appears well and is not in acute distress. Her vital signs are stable. There is prominent exotropia of the left eye. She has hearing aids in both ears.
  • Gait Analysis: The patient walks independently without assistive devices. She walks with a left-sided limp. The stance phase is prolonged on the left leg. During the swing phase, the left leg appears straight and stiff. The right leg demonstrates wide, stiff-legged circumduction during swing phase. Step length is reduced on the left side. There is no dragging of the feet. Turning is smooth.
  • Inspection: There are no skin discolorations, rashes, or bruising of the lower extremities. Hair and nail distribution are normal. There is no visible swelling. Muscle bulk appears normal and symmetric bilaterally. The knees appear slightly enlarged bilaterally but show normal alignment both frontally and laterally. There is no genu varum or valgus deformity.
  • Palpation: Skin temperature is normal. There are no swellings or deformities detected. Maximal tenderness is present at the joint line of the tibiofemoral joint. Moderate tenderness is present on palpation over the patella, patellar tendon, and anteromedial crest of the tibia. There is no tenderness over the muscles, superior pole of the patella, fibular head, pes anserine bursa, Gerdy’s tubercle, or popliteal fossa.
  • Range of Motion: Passive range of motion is normal and symmetric bilaterally. Active range of motion is slightly decreased on the left leg due to pain.
  • Special Tests: There is no laxity of the medial collateral ligament or lateral collateral ligament. The anterior drawer test is negative. The posterior drawer test is negative. The patellar ballottement test is negative. The fluid wave test is negative. No Baker’s cyst is palpated.
  • Vascular Examination: The popliteal, posterior tibialis, and dorsalis pedis pulses are palpable and symmetric bilaterally.
  • Neurological Examination: Power is 4/5 on both legs, except for 3/5 left knee flexion and extension. Reflexes not assessed.

Problem Representation

62 year old woman with chronic gait difficulty presents with acute-on-chronic left-sided knee pain and weakness in flexion/extension after a fall from standing height, suggesting chronic degenerative joint disease +/- central neurological changes.

CDM table

Most Likely Diagnoses

DiagnosisSupporting FeaturesRefuting Features
Cervical MyelopathyProgressive bilateral leg weakness (4/5 power); spastic gait pattern with stiff-legged circumduction; prolonged stance phase; chronic progressive course over years; age 62 (typical for cervical spondylosis); altered gait mechanics could explain secondary knee painCommunication difficulties not typically prominent in isolated myelopathy; no documented upper extremity symptoms; reflexes and upper motor neuron signs not assessed
Normal Pressure HydrocephalusProgressive gait disturbance with wide-based, stiff gait; cognitive/communication difficulties; chronic progressive course (~1 year by patient report, years per collateral history); classic triad presentationUrinary incontinence not mentioned; turning described as smooth (typically impaired in NPH); no documented cognitive testing to confirm dementia
Neurodegenerative Disorder with Motor and Cognitive FeaturesProgressive bilateral leg weakness; communication difficulties with language comprehension impairment; spastic gait with upper motor neuron features; bilateral hearing loss; exotropia (may suggest neurological disease); chronic progressive courseRelatively preserved function (independent ambulation); no family history documented; no tremor, rigidity, or other parkinsonian features noted
Corticobasal Syndrome or Atypical Parkinsonian DisorderProgressive asymmetric motor symptoms; communication/language difficulties; exotropia; spastic features; chronic progressive courseNo documented apraxia, alien limb phenomenon, dystonia, or cortical sensory loss; no tremor or rigidity noted; turning smooth (typically impaired in parkinsonism)

Critical Diagnoses Not to Miss

DiagnosisSupporting FeaturesRefuting Features
Compressive Spinal Lesion or Structural CNS PathologyProgressive bilateral leg weakness; spastic gait pattern; chronic progressive course; requires urgent treatment to prevent permanent disabilityNo acute neurological deterioration; no documented sensory level; no bowel/bladder symptoms mentioned
Amyotrophic Lateral Sclerosis/Motor Neuron DiseaseProgressive bilateral leg weakness; potential upper motor neuron features (spastic gait); chronic progressive courseNo documented lower motor neuron signs (fasciculations, atrophy, hyporeflexia); no bulbar symptoms; muscle bulk appears normal and symmetric; communication difficulties may suggest cognitive involvement atypical for pure ALS
Frontotemporal Dementia-Motor Neuron Disease SpectrumProgressive communication difficulties with language comprehension issues; motor weakness and gait abnormalities; bilateral involvementNo documented bulbar symptoms (dysphagia, dysarthria); no behavioral changes mentioned; no fasciculations noted; relatively preserved function
Stroke/Subcortical Vascular DiseaseCommunication difficulties; bilateral leg weakness; gait abnormalities; bilateral hearing loss (vascular risk)Gradual progressive onset over years (not stepwise); no acute events documented; smooth turning suggests preserved basal ganglia function

Less Likely Diagnoses

DiagnosisSupporting FeaturesRefuting Features
Osteoarthritis with Incidental/Secondary FindingsAge 62; bilateral knee enlargement; maximal tenderness at tibiofemoral joint line; moderate tenderness over patella and patellar tendon; knee painDoes not explain bilateral leg weakness, spastic gait pattern, or communication difficulties; normal muscle bulk argues against disuse atrophy from chronic pain

Key Additional History and Follow-up Tests:

  • Detailed neurological history: Onset and progression of weakness, presence of fasciculations, muscle cramps, dysphagia, dysarthria, changes in handwriting or fine motor skills, bowel/bladder dysfunction, sensory symptoms, family history of neurodegenerative disease

  • Cognitive and language assessment: Formal neuropsychological testing to characterize the nature of communication difficulties (aphasia vs. dysarthria vs. hearing impairment), executive function, memory domains

  • MRI of cervical spine and brain: Essential to evaluate for cervical myelopathy, structural lesions, hydrocephalus, patterns of atrophy suggesting specific neurodegenerative disorders, and vascular disease

  • Electromyography and nerve conduction studies: To assess for lower motor neuron involvement, distinguish between myelopathy and motor neuron disease, and evaluate for peripheral neuropathy

  • Formal audiometry: To distinguish hearing loss from primary language/cognitive impairment

  • Reflexes assessment: Hyperreflexia, clonus, Babinski sign, Hoffmann’s sign to confirm upper motor neuron involvement

  • Gait analysis and functional testing: Timed up and go test, assessment of turning, balance testing to characterize gait disorder

  • Laboratory studies: Vitamin B12, thyroid function, inflammatory markers, creatine kinase to exclude metabolic or inflammatory causes of weakness

  • Lumbar puncture with CSF analysis: If NPH suspected, can assess opening pressure and consider large-volume tap test for diagnostic and prognostic purposes

  • Knee imaging (X-ray or MRI): To evaluate the extent of osteoarthritis and exclude other causes of knee pain, though this is secondary to establishing the neurological diagnosis

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC5850553/#s200510
  2. https://sci-hub.ru/10.1056/NEJMra2304088
  3. https://rheuminfo.com/en/physician-tools/knee-examination/